Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6–89.6) years with a median of 3 prior lines (range 1–9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1–5.6) months and 13.3 (95% CI 10.6–16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6–5.3) months and 10.5 (95% CI 8.5–13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients.
尽管新型药物不断问世，多发性骨髓瘤（MM）仍无法治愈。这项多中心回顾性队列研究利用加拿大骨髓瘤研究组数据库，描述了对抗CD38单克隆抗体（mAb）难治性MM患者随后接受标准治疗方案（SoC）的真实世界疗效。研究将三重级别难治性（TCR）疾病（即对蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体均耐药）患者作为一个独立队列进行分析。总体上，663名患者在抗CD38单克隆抗体治疗期间出现疾病进展，其中466人接受了后续治疗（纳入346名接受标准治疗方案的患者，排除120名参与临床试验接受研究性药物的患者）。开始后续标准治疗的中位年龄为67.9岁（范围39.6-89.6岁），此前中位治疗线数为3线（范围1-9线）。后续治疗开始后的中位无进展生存期（PFS）和总生存期（OS）分别为4.6个月（95% CI 4.1-5.6）和13.3个月（95% CI 10.6-16.6）。TCR疾病患者（n=199）的中位PFS和OS分别为4.4个月（95% CI 3.6-5.3）和10.5个月（95% CI 8.5-13.8）。我们的结果进一步证实，真实世界中复发MM患者，尤其是TCR疾病患者，预后极差。针对这些患者，开发并获得有效治疗手段仍然是亟待满足的迫切需求。
肿瘤(癌症)患者之家